OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio
Masayuki Kaneko, Mamoru Narukawa
Clinical Drug Investigation (2018) Vol. 39, Iss. 2, pp. 179-186
Closed Access | Times Cited: 12
Masayuki Kaneko, Mamoru Narukawa
Clinical Drug Investigation (2018) Vol. 39, Iss. 2, pp. 179-186
Closed Access | Times Cited: 12
Showing 12 citing articles:
An update on the safety of SGLT2 inhibitors
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155
Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes
David E. Kloecker, Melanie J. Davies, Kamlesh Khunti, et al.
Annals of Internal Medicine (2020) Vol. 172, Iss. 8, pp. 541-541
Open Access | Times Cited: 75
David E. Kloecker, Melanie J. Davies, Kamlesh Khunti, et al.
Annals of Internal Medicine (2020) Vol. 172, Iss. 8, pp. 541-541
Open Access | Times Cited: 75
Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis
Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 61
Takayoshi Kanie, Atsushi Mizuno, Yoshimitsu Takaoka, et al.
Cochrane library (2021) Vol. 2021, Iss. 10
Open Access | Times Cited: 61
<p>Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide</p>
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 70
Bryce C. Simes, Gordon G. MacGregor
Diabetes Metabolic Syndrome and Obesity (2019) Vol. Volume 12, pp. 2125-2136
Open Access | Times Cited: 70
The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial
Clare Arnott, Yuli Huang, Brendon L. Neuen, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 10, pp. 1753-1766
Open Access | Times Cited: 39
Clare Arnott, Yuli Huang, Brendon L. Neuen, et al.
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 10, pp. 1753-1766
Open Access | Times Cited: 39
Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials
Ze Chen, Gerui Li
Clinical Drug Investigation (2019) Vol. 39, Iss. 6, pp. 521-531
Closed Access | Times Cited: 22
Ze Chen, Gerui Li
Clinical Drug Investigation (2019) Vol. 39, Iss. 6, pp. 521-531
Closed Access | Times Cited: 22
The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review
Giuseppe Miceli, Maria Grazia Basso, Andrea Roberta Pennacchio, et al.
Medicina (2024) Vol. 60, Iss. 11, pp. 1796-1796
Open Access | Times Cited: 1
Giuseppe Miceli, Maria Grazia Basso, Andrea Roberta Pennacchio, et al.
Medicina (2024) Vol. 60, Iss. 11, pp. 1796-1796
Open Access | Times Cited: 1
Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus: Results of 24‐month interim analysis of a long‐term post‐marketing study (J‐STEP/LT)
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, et al.
Journal of Diabetes Investigation (2020) Vol. 11, Iss. 4, pp. 906-916
Open Access | Times Cited: 10
Kazunori Utsunomiya, Seigo Kakiuchi, Masayuki Senda, et al.
Journal of Diabetes Investigation (2020) Vol. 11, Iss. 4, pp. 906-916
Open Access | Times Cited: 10
Update on: effects of anti-diabetic drugs on bone metabolism
Guillaume Mabilleau, Béatrice Bouvard
Expert Review of Endocrinology & Metabolism (2020) Vol. 15, Iss. 6, pp. 415-430
Closed Access | Times Cited: 6
Guillaume Mabilleau, Béatrice Bouvard
Expert Review of Endocrinology & Metabolism (2020) Vol. 15, Iss. 6, pp. 415-430
Closed Access | Times Cited: 6
Fracture risk in patients with type 2 diabetes aged ≥50 years related to HbA1c, acute complications, BMI and SGLT2i-use in the DPV registry
Alexander J. Eckert, Julia K. Mader, Marcus Altmeier, et al.
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 10, pp. 107664-107664
Open Access | Times Cited: 5
Alexander J. Eckert, Julia K. Mader, Marcus Altmeier, et al.
Journal of Diabetes and its Complications (2020) Vol. 34, Iss. 10, pp. 107664-107664
Open Access | Times Cited: 5
Sodium–Glucose Cotransporter-2 Inhibitors and the Risk of Amputation: What Is Currently Known?
Anne Misher, Andrea Ampuero, Rebecca Phan, et al.
American Journal of Therapeutics (2020) Vol. 28, Iss. 1, pp. e96-e110
Closed Access | Times Cited: 3
Anne Misher, Andrea Ampuero, Rebecca Phan, et al.
American Journal of Therapeutics (2020) Vol. 28, Iss. 1, pp. e96-e110
Closed Access | Times Cited: 3
Recent Advances in the Development of Type 2 Sodium-Glucose Cotransporter Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Ana Karen Estrada, Timoteo Delgado-Maldonado, Edgar E. Lara‐Ramírez, et al.
Mini-Reviews in Medicinal Chemistry (2021) Vol. 22, Iss. 4, pp. 586-599
Closed Access | Times Cited: 3
Ana Karen Estrada, Timoteo Delgado-Maldonado, Edgar E. Lara‐Ramírez, et al.
Mini-Reviews in Medicinal Chemistry (2021) Vol. 22, Iss. 4, pp. 586-599
Closed Access | Times Cited: 3
